Overview

Study Evaluating PAZ-417 in Healthy Young/Elderly

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety and tolerability of single, ascending doses of PAZ-417 in healthy young and healthy elderly subjects. The effect of a high fat meal on the metabolism of PAZ-417 will also be studied, along with blood levels of PAZ-417 . Changes in cognitive function will be assessed.
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer